Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs.
Curr Ther Res Clin Exp
; 100: 100742, 2024.
Article
en En
| MEDLINE
| ID: mdl-38617894
ABSTRACT
Background:
Concerns of intraocular inflammation associated with intravitreal administration of anti-VEGF drugs have been risen and the exact mechanism is not yet elucidated.Objective:
To explore the relationship between immunogenicity and intraocular inflammation in intravitreal anti-VEGF drugs.Methods:
This review examines the immunogenicity of individual intravitreal anti-VEGF drugs and their potential link to intraocular inflammation.Results:
We suggest that the main cause of intraocular inflammation is the presence of pre-existing and treatment-induced antidrug antibodies, along with considerations related to the molecular structure, which includes the drug's format and size.Conclusions:
Researchers and clinicians involved in the advancement of new anti-VEGF drugs should take into consideration the factors related to intraocular inflammation that have been discussed.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Curr Ther Res Clin Exp
Año:
2024
Tipo del documento:
Article